Factor VIII levels at 42%, 4 days after infusion
Hypothetical patient
and scenario
Copay Savings
for ALTUVIIIO*
*Terms and restrictions apply.

NOW APPROVED

NOW APPROVED

A new class of once-weekly infusion

Factor Up with ALTUVIIIO

Factor VIII replacement therapy
with higher-for-longer levels in the near‑normal to normal range (over 40%) for most of the week

Switch It Up
Switch It Up
Copay Savings
for ALTUVIIIO*
*Terms and restrictions apply.
Connect with a CoRe Manager

CONNECT WITH A CoRe MANAGER TODAY!

Sanofi Hemophilia Community
Relations and Education (CoRe)

Managers provide information about ALTUVIIIO, living with
hemophilia,
and treatment options.

Get Connected Now!Get Connected Now!
Curved red arrow icon pointing upwards

HIGHER FACTOR
LEVELS FOR LONGER

Above 40% for most of
the week (near-normal
to normal range).*†

48

HOUR HALF-LIFE
IN ADULTS

In a Phase 3 study,† ALTUVIIIO offered adults
the longest half-life of
any Factor VIII therapy.

0.7

BLEEDS
PER YEAR‡

Mean annual bleed rate observed in 128 people previously treated with prophylaxis therapy.†

Calendar icon showing 1x weekly

FREEDOM AND
FLEXIBILITY OF A
ONCE-WEEKLY INFUSION

ALTUVIIIO can also be
used for on-demand and
perioperative use.

*Average trough levels were 18% for adults 18 years and older, 9% for adolescents aged 12 years to under 18 years, 10% for children aged 6 years to under 12 years, and 7% for children aged 1 year to under 6 years.

†159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.

‡Data based on treated bleeds.

Curved red arrow icon pointing upwards

HIGHER FACTOR LEVELS FOR LONGER

Above 40% for most of the week (near-normal to normal range).*†

48

HOUR HALF-LIFE
IN ADULTS

In a Phase 3 study,†
ALTUVIIIO offered adults
the longest half-life of
any Factor VIII therapy.

0.7

BLEEDS
PER YEAR‡

Mean annual bleed rate observed in 128 people previously treated with prophylaxis therapy.†

Calendar icon showing 1x weekly

FREEDOM AND FLEXIBILITY OF A ONCE-WEEKLY INFUSION

ALTUVIIIO can also be
used for on-demand
and perioperative use.

*Average trough levels were 18% for adults 18 years and older, 9% for adolescents aged 12 years to under 18 years, 10% for children aged 6 years to under 12 years, and 7% for children aged 1 year to under 6 years.

†159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.

‡Data based on treated bleeds.

Connect With a CoRe Manager

Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.

Connect with a CoRe Manager

Get Informed. Stay Informed.

Let’s stay in touch. We’ll occasionally send you important information on hemophilia A and ALTUVIIIO.